|View printer-friendly version|
|Worldwide Clinical Trials Selected by BrainStorm as CRO for Phase 3 NurOwn Trial in ALS|
"Selecting a CRO is a critical step before initiating patient enrollment into our Phase 3 study of NurOwn in the treatment of ALS," said
With support from Worldwide, BrainStorm will proceed with conducting a randomized, double-blind, placebo-controlled multi-dose Phase 3 trial that will be conducted at multiple sites.
About Worldwide Clinical Trials:
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/worldwide-clinical-trials-selected-by-brainstorm-as-cro-for-phase-3-nurown-trial-in-als-300482969.html